{"log_id": 1021606691289646487, "direction": 0, "words_result_num": 29, "words_result": [{"probability": {"variance": 0.00026, "average": 0.98934, "min": 0.961454}, "location": {"width": 101, "top": 169, "height": 30, "left": 235}, "words": "核准日期"}, {"probability": {"variance": 1e-06, "average": 0.999455, "min": 0.99825}, "location": {"width": 100, "top": 204, "height": 27, "left": 235}, "words": "修改日期"}, {"probability": {"variance": 1.2e-05, "average": 0.998406, "min": 0.982128}, "location": {"width": 717, "top": 248, "height": 53, "left": 288}, "words": "注射用重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白说明书"}, {"probability": {"variance": 2.5e-05, "average": 0.997435, "min": 0.979393}, "location": {"width": 408, "top": 303, "height": 41, "left": 441}, "words": "请仔细阅读说明书并在医师指导下使用"}, {"probability": {"variance": 0, "average": 0.999464, "min": 0.999432}, "location": {"width": 50, "top": 335, "height": 28, "left": 232}, "words": "警告"}, {"probability": {"variance": 0, "average": 0.999631, "min": 0.998657}, "location": {"width": 97, "top": 375, "height": 30, "left": 232}, "words": "严重感染"}, {"probability": {"variance": 3e-06, "average": 0.999076, "min": 0.991345}, "location": {"width": 774, "top": 422, "height": 51, "left": 276}, "words": "使用本品进行治疗的患者发生严重感染的风险增高,可能导致住院或死亡"}, {"probability": {"variance": 3.7e-05, "average": 0.997225, "min": 0.968526}, "location": {"width": 792, "top": 470, "height": 50, "left": 236}, "words": "(见警告和不良反应)。而绝大多数出现上述情况的患者同时合用免疫抑制剂"}, {"probability": {"variance": 4.8e-05, "average": 0.995146, "min": 0.976236}, "location": {"width": 244, "top": 518, "height": 35, "left": 224}, "words": "如甲氨蝶呤或皮质激素"}, {"probability": {"variance": 2.8e-05, "average": 0.998027, "min": 0.975431}, "location": {"width": 482, "top": 565, "height": 41, "left": 223}, "words": "一旦患者发生严重感染或脓毒血症应停用本品"}, {"probability": {"variance": 0.025101, "average": 0.939597, "min": 0.520427}, "location": {"width": 198, "top": 613, "height": 34, "left": 221}, "words": "己报告的感染包括"}, {"probability": {"variance": 0, "average": 0.999433, "min": 0.999006}, "location": {"width": 91, "top": 642, "height": 41, "left": 921}, "words": "公司"}, {"probability": {"variance": 0.012094, "average": 0.975438, "min": 0.358461}, "location": {"width": 783, "top": 657, "height": 58, "left": 262}, "words": "活动性结核感染,包括复发的潜伏性结核感染。结核感染患者复出现播散"}, {"probability": {"variance": 0.000489, "average": 0.99092, "min": 0.896045}, "location": {"width": 761, "top": 702, "height": 62, "left": 259}, "words": "性或肺外病变。患者使用本品前和用药过程中位检测潜伏性的结核感染"}, {"probability": {"variance": 9.9e-05, "average": 0.997178, "min": 0.955171}, "location": {"width": 459, "top": 756, "height": 42, "left": 259}, "words": "使用本品治疗前必须治疗潜伏性的结核感染"}, {"probability": {"variance": 0.003279, "average": 0.977957, "min": 0.784092}, "location": {"width": 785, "top": 801, "height": 56, "left": 257}, "words": "侵袭性真菌感染,包括组织胞浆菌病球孢子菌病,念珠菌病霉"}, {"probability": {"variance": 3e-06, "average": 0.998753, "min": 0.993978}, "location": {"width": 782, "top": 851, "height": 50, "left": 255}, "words": "生菌病,和肺孢子虫病。患者有组织胞浆菌病或其他侵袭性真菌感染者,可"}, {"probability": {"variance": 0.010898, "average": 0.965709, "min": 0.575038}, "location": {"width": 785, "top": 895, "height": 57, "left": 253}, "words": "能呈现播散性而非局限性病变,一些活动性感染患者的组织胞浆菌病的抗原"}, {"probability": {"variance": 0.0033, "average": 0.982097, "min": 0.755739}, "location": {"width": 783, "top": 948, "height": 46, "left": 254}, "words": "和抗体检测可能为阴性患者的侵袭性真菌感染有发展为严重全身性疾病风"}, {"probability": {"variance": 0.005674, "average": 0.973669, "min": 0.692141}, "location": {"width": 383, "top": 996, "height": 40, "left": 252}, "words": "险时,应考虑给予经验性抗真菌治疗"}, {"probability": {"variance": 0.000237, "average": 0.995002, "min": 0.930741}, "location": {"width": 784, "top": 1039, "height": 56, "left": 251}, "words": "因机会致病菌导致的细菌性、病毒性和其他感染,包括军团菌属和利斯塔氏"}, {"probability": {"variance": 0, "average": 0.99968, "min": 0.999444}, "location": {"width": 49, "top": 1090, "height": 28, "left": 251}, "words": "菌属"}, {"probability": {"variance": 1.9e-05, "average": 0.998673, "min": 0.974863}, "location": {"width": 779, "top": 1136, "height": 50, "left": 252}, "words": "慢性或反感染的患者使用本品治疗之前,应当仔细评估其承担的风险和受"}, {"probability": {"variance": 0, "average": 0.999941, "min": 0.999941}, "location": {"width": 27, "top": 1185, "height": 28, "left": 204}, "words": "益"}, {"probability": {"variance": 4e-06, "average": 0.998837, "min": 0.992509}, "location": {"width": 778, "top": 1232, "height": 49, "left": 251}, "words": "使用本品治疗时和治疗后,应严密监测患者感染症状和体征的变化,包括那"}, {"probability": {"variance": 3e-06, "average": 0.999245, "min": 0.991486}, "location": {"width": 745, "top": 1279, "height": 48, "left": 199}, "words": "些治疗前的潜伏性结核感染检测结果呈阴性而可能发生结核感染的患者"}, {"probability": {"variance": 3e-06, "average": 0.997882, "min": 0.994999}, "location": {"width": 100, "top": 1329, "height": 30, "left": 200}, "words": "恶性肿瘤"}, {"probability": {"variance": 0.001159, "average": 0.992711, "min": 0.797848}, "location": {"width": 777, "top": 1375, "height": 49, "left": 247}, "words": "有报告使用TNF-抑制剂,包括本品,治疗的儿童和青少年患者发生淋巴瘤"}, {"probability": {"variance": 1e-06, "average": 0.999043, "min": 0.996084}, "location": {"width": 341, "top": 1421, "height": 39, "left": 197}, "words": "和其他恶性肿瘤,有些是致命的"}], "language": 3}